Seaport Therapeutics, Inc. Common Stock(SPTX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$19.98
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SPTX

11/13/2026: SPTX (1-star) is currently NOT-A-BUY. Pass it for now.

Seaport Therapeutics is a clinical-stage biotechnology company focused on developing oral neuropsychiatric medicines for conditions like depression and anxiety. The company's primary strength lies in its proprietary Glyph platform, which aims to improve drug bioavailability and reduce side effects. Investors are drawn to its potential for high growth as it advances lead candidates like GlyphAllo through clinical trials. However, it faces significant risks as a pre-revenue company, including the inherent uncertainty of clinical development, the need for future funding, and stiff competition from established pharmaceutical players. It is best suited for growth-oriented investors with high risk tolerance who monitor upcoming clinical trial results closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company is a clinical-stage biotech with high-growth potential linked to its proprietary technology platform.
Momentum investorStrong fit while signal remains positiveThe stock may attract momentum following positive clinical trial data announcements.
Value investorWeak fitThe company is unprofitable and lacks the earnings history required for traditional value investing.
Dividend investorWeak fitThe company does not pay dividends and is currently in a capital-intensive development phase.
Low-risk investorWeak fitThe high volatility and clinical risk associated with biotech startups make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotech stocks are highly sensitive to trial results and news flow.
Valuation riskMedium / highValuations for pre-revenue biotech companies are often based on subjective probabilities of clinical success.
Competition risk (CNS drug development)HighThe company faces deep-pocketed competitors in the depression and anxiety drug markets.
Business qualityMediumThe company is an early-stage venture with unproven products.
Dividend incomeLow / noneThere is no income component to the investment.
Execution riskHighSuccess depends heavily on achieving clinical trial endpoints and navigating regulatory approval.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.07B USD
Price to earnings Ratio -
1Y Target Price 37.12
Price to earnings Ratio -
1Y Target Price 37.12
Volume (30-day avg) 242.7K shares
Beta -
52 Weeks Range 14.85 - 28.38
Updated Date 11/14/2026
52 Weeks Range 14.85 - 28.38
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -4.35

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SPTX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SPTX has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-59.7%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
SPTX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
SPTX's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-59.7%, negative) and free-cash-flow growth (-163.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 73.4% and approximately 34.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 34.99% supports management-shareholder alignment.

Top 5 Institutional Investors

ARCH VENTURE CORP 11.76%
General Atlantic Llc 11.40%
Sofinnova Ventures 6.66%
The Goldman Sachs Group Inc 4.07%
TRV GP VI, LLC 3.85%

Unit Economics (Per $1K Revenue)

★★★★★
SPTX generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.04% (Tax Credit)

Quantitative Style Profile

★★★★★
SPTX has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Drug DevelopmentClinical and preclinical development of Glyph-based oral therapeutics.The company earns no revenue yet; it is investing capital to develop drugs that, if successful, will be sold to patients via pharmaceutical distribution channels.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 791.82M
Price to Sales(TTM) -
Enterprise Value 791.82M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 53.53M
Shares Floating 18.43M
Shares Outstanding 53.53M
Shares Floating 18.43M
Percent Insiders 34.99
Percent Institutions 73.44

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.